Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer

Abstract Background Resected HER2 breast cancer patients treated with adjuvant trastuzumab and chemotherapy have superior survival compared to patients treated with chemotherapy alone. We previously showed that trastuzumab and chemotherapy induce HER2-specific antibodies which correlate with improve...

Full description

Bibliographic Details
Main Authors: Nadine Norton, Nicholas Fox, Christie-Ann McCarl, Kathleen S. Tenner, Karla Ballman, Courtney L. Erskine, Brian M. Necela, Donald Northfelt, Winston W. Tan, Carmen Calfa, Mark Pegram, Gerardo Colon-Otero, Edith A. Perez, Raphael Clynes, Keith L. Knutson
Format: Article
Language:English
Published: BMC 2018-06-01
Series:Breast Cancer Research
Subjects:
Trastuzumab
Adaptive immune response
HER2 + 
Disease-free survival
Online Access:http://link.springer.com/article/10.1186/s13058-018-0989-8

Internet

http://link.springer.com/article/10.1186/s13058-018-0989-8

Similar Items